Introduction
Valvular heart disease is a growing clinical problem with significant morbidity and
mortality. Surgical valve replacement using mechanical or tissue prosthesis has remained
the preferred therapy for several decades. In contrast to mechanical valves, the use
of bioprosthetic valves to treat significant aortic valve stenosis (AS) or aortic
valve regurgitation (AR) in the native aortic valve has continued to increase over
time.1, 2 Bioprosthetic valves are advantageous to patients as they negate the need
for long‐term anticoagulation therapy; however, they have limited durability and are
expected to degenerate within 5 to 20 years.2, 3, 4 The current standard of care for
patients with a degenerated bioprosthetic valve is surgical valve replacement; however,
the morbidity and mortality for reoperation is significant because of the technical
complexity of the re‐do sternotomy, and also because most of these patients are elderly
with multiple comorbid conditions such as prior coronary artery bypass surgery, diabetes
mellitus, and cerebrovascular disease.2, 5, 6
Although transcatheter heart valves (THV) were initially designed to treat aortic
stenosis, the design yields to its use for other indications. The first use of a THV
device to treat a failing bioprosthetic heart valve in the aortic position was reported
in 2007.7 Since then, valve‐in‐valve (VIV) has become a feasible alternative for treating
patients who have degenerated bioprosthetic aortic valves and who are at increased
risk of adverse perioperative events.2, 5, 6 VIV is also emerging as a treatment option
for patients with failed bioprosthesis in the mitral position. Hundreds of patients with
failed mitral bioprosthesis have been treated worldwide with the off‐label use of
aortic transcatheter heart valves.8, 9
The procedural success rate for aortic VIV transcatheter aortic valve replacement
(TAVR) was 93.1% based on the preliminary data from the Valve‐in‐Valve International
Data (VIVID) registry.6 In the VIVID registry, the overall 1‐year survival was 83.2%
in patients who underwent transcatheter VIV implantation for degenerated bioprosthetic
aortic valves.6 The US Food and Drug Administration had approved an expanded indication
for the use of the balloon‐expandable Sapien, Sapien XT valves (Edwards Lifesciences),
and the self‐expanding CoreValve System (Medtronic Inc) for aortic VIV implantation.
The Sapien 3 (S3) (Edwards Lifesciences) valve is the latest iteration of the US Food
and Drug Administration–approved balloon‐expandable THV, and it has unique characteristics
compared with previous valves. The use of S3 THV was expanded by the US Food and Drug
Administration on June 5, 2017 not only for VIV implantation inside a failed bioprosthetic
aortic valve, but also for a failed bioprosthetic mitral valve; this is the first
approval of any THV for both aortic and mitral VIV implantation.
Several new features of the S3 THV, especially its outer skirt and the ability to
overexpand its stent frame,10 may have an impact for choosing the optimal size of
S3 THV for aortic and mitral VIV implantation.
In this article we evaluate existing methods with respect to utilization of the S3
valve in aortic and mitral VIV procedures, describe bioprosthetic valve sizing terminology
(Figure 1), and discuss preprocedural sizing as well as relevant intraprocedural factors
and techniques used for a successful VIV implant.
Figure 1
Surgical bioprosthesis sizing terms. A schematic representation of a cross‐section
through a failed bioprosthetic valve is shown. Valve size measurements may be defined
in a number of ways. Manufacturer label size is variable and does not usually indicate
the internal diameter of the valve. S‐ID is used to indicate the inner diameter of
the valve struts/frame, including overlying fabric. T‐ID accounts for the leaflets
and sutures (represented in blue) sewn within the stent frame, whereas CT‐ID also
includes any accumulated pannus or calcification (represented in orange) within the
degenerated bioprosthesis. CT‐ID indicates computed‐tomography inner diameter; S‐ID,
stent inner diameter; T‐ID, true inner diameter.
Sizing and Deployment
In general terms, “under/oversizing” refers to the degree to which a THV is smaller/larger
than the measured annulus or bioprosthesis internal diameter, respectively. A degree
of oversizing is essential—particularly when implanting self‐expanding valves—to ensure
THV anchoring and stability after deployment. During native valve TAVR, excessive
oversizing may increase the risk of heart block requiring permanent pacemaker implantation
and annulus rupture. How much oversize is required to ensure adequate fixation and
at the same time avoid incomplete device expansion of balloon‐expandable THVs is unclear,
and hence an oversize in the range of 2 to 3 mm is usually practiced.
In this review, “under/overexpansion” refers specifically to the balloon filling volume
strategy used to deploy the S3 THV, with reference to the nominal filling volume.
For example, overexpansion of the 23‐mm S3 THV, with an extra 2 mL of filling volume,
results in a prosthesis diameter of ≈24 mm—mainly at the in‐ and outflow part of the
valve frame—while preserving normal valve function.10 This under/overexpansion capability
of the S3 means that the size of the implanted THV can be more precisely tailored
to the dimensions of the bioprosthesis during VIV procedures, thus avoiding excessive
oversizing. As a general principle during VIV procedures, we recommend implanting
the smallest size S3 device that can be adequately deployed and anchored to achieve
a minimum of 1 mm oversizing (Figure 2), within the constraints of the bioprosthesis
and notwithstanding other anatomical considerations.
Figure 2
Algorithm for determining the choice of S3 THV size. This simplified flow chart can
be used during VIV TAVR to facilitate selection of the S3 THV size, and guide when
balloon sizing may be appropriate. A minimum of 1 mm oversizing is required in order
to ensure adequate anchoring of the S3 THV within the bioprosthesis. Use of the smallest
possible THV reduces the risk of excessive flaring of the outflow portion of the stent
frame. N.B. In small bioprosthetic valves (label size ≤21), the risk of patient–prosthesis
mismatch is high after VIV TAVR. High‐pressure balloon postdilatation with bioprosthetic
valve fracture may enable implantation of a larger size THV with improved transvalvular
gradient. CT‐ID indicates computed‐tomography inner diameter; S3, Sapien 3; THV, transcatheter
heart valve; T‐ID, true inner diameter; VIV TAVR, valve‐in‐valve transcatheter aortic
valve replacement.
Foreshortening
Unlike preceding iterations of balloon‐expandable THV, S3 foreshortening during deployment
occurs almost exclusively from the inflow side of the device. This technical feature
has implications when choosing the deployment height of the valve, particularly as
deliberate under‐ or overexpansion will result in a lesser or greater degree of foreshortening,
respectively.
Appropriate Valve Expansion
Appropriate S3 expansion is important to achieve an optimal hemodynamic outcome. An
inadequately expanded THV may be at risk of elevated transvalvular gradient because
of inadequate leaflet expansion and mobility, also potentially increasing the risk
of accelerated leaflet degeneration.1, 2, 4, 11
Measure of VIV Success
The requirements for a successful VIV implantation are as follows: secure anchoring
of the THV within the failed bioprosthesis, a good seal around the valve to eliminate
intervalvular leak, patent coronary arteries (in aortic VIV) and left ventricular
outflow tract (in mitral VIV), a low gradient across the newly implanted THV, and
lack of central regurgitation. Selection of the appropriate size THV and preprocedural
identification of potential complications are key to a successful VIV procedure.
Identification and Sizing of the Failed Bioprosthetic Valve
An important component of performing the VIV procedure starts with an in‐depth understanding
of the failed bioprosthetic valve, which includes the following: the type of valve
used (stented, stentless, sutureless, transcatheter valve), its structural elements,
the technical details of the primary valve surgery (intra‐annular versus supra‐annular),
and the cause of bioprosthetic valve failure (wear and tear, calcification, endocarditis,
thrombosis, leaflet dysfunction, and pannus formation).1, 2, 4, 5, 12 Selection of
the THV size for the aortic and mitral VIV implantation depends on many factors listed
above.
Failed Bioprosthetic Valve Inner Diameter
The type of bioprosthesis and manufacturer‐defined label size could be obtained from
the operative report. When this information is not available, the type of implant
may be identified by fluoroscopy, chest radiograph, and/or cardiac multidetector computed
tomography (MDCT).5 The sizing and labeling of the surgical bioprosthetic valves are
not standardized and vary widely based on the different manufacturers. The minimum
internal diameter of the surgical bioprosthetic valve may vary markedly from the given
labeled valve size1, 2, 4, 5 (Figure 1); label size alone is therefore not suitable
as a guide to THV size selection.
The “true” inner diameter (T‐ID) of the surgical bioprosthesis is one of the most
important pieces of information needed for selecting the size of the THV for the aortic
or mitral VIV procedure.4 It is important to note that most bioprosthetic valves have
a “stent” inner diameter, which consists of the frame/skeleton of the valve, including
the overlying fabric, and the T‐ID, which takes into account the leaflets sewn within
the valve frame13 (Figure 1). The term “neo‐annulus” has been used to describe the
narrowest physical plane—determined in vitro by balloon inflation—of a surgical bioprosthesis,
and it is this benchtop dimension that determines the T‐ID. In most bioprosthesis
types, this minimum diameter is located at the level of the sewing ring.14 Another
crucial point to remember is that when we factor in the additional space taken up
by degenerated leaflets and accumulated material in the failed bioprosthesis including
pannus formation, the actual internal diameter of that valve is likely to be even
less than the T‐ID. In addition to providing information regarding the degree and
distribution of calcific degeneration, accumulated material at the level of the sewing
ring within a bioprosthesis can be assessed using contrast‐enhanced MDCT. We propose
using the definition “CT” inner diameter (CT‐ID) to describe this minimum internal
diameter in degenerated in vivo bioprosthetic valves (Figure 1). Use of the CT‐ID
may indicate that a smaller S3 valve is preferable in order to achieve an optimal
VIV result (Figures 3 and 4).
Figure 3
Central regurgitation after extensive oversizing of a 26‐mm S3 THV within a St. Jude
Epic 27‐mm bioprosthesis in the mitral position. Although the T‐ID of the 27‐mm St.
Jude Epic is 22.5 mm, a mean preoperative CT‐ID of 18.2 mm was measured in this degenerated
bioprosthesis (Panel A1). The VIV app recommends use of a 26‐mm S3 THV; however, deployment
resulted in underexpansion of the device within the bioprosthesis and extensive flaring
of the outflow portion of the frame (Panels B1 to B4), associated with central regurgitation
(Panels C1 and C2). CT‐ID indicates computed‐tomography inner diameter; S3, Sapien
3; THV, transcatheter heart valve; T‐ID, true inner diameter; VIV, valve‐in‐valve.
Figure 4
Mitral VIV. S3 valve choice based on CT‐ID, balloon‐sizing, and tug‐test. Case of
S3 26‐mm valve inside an Epic 31 mm (St. Jude Medical) with a T‐ID of 26.5 mm. The
VIV Mitral App recommends implanting a S3 29‐mm valve. Based on the CT‐ID of 18.7 mm
and balloon‐sizing and tug‐test with a 25‐mm balloon, the decision was to deploy a
26‐mm S3 valve with nominal filling volume. A1. Epic 31‐mm (St. Jude Medical) valve:
CT‐ID was measured at 18.7 mm. A2. Aorto‐mitral angle: 138 degrees. B1. Coplanar view
of the mitral valve. B2. Balloon‐sizing and tug‐test with a 25‐mm Edwards balloon.
B3. S3 26‐mm positioning towards left ventricle because of expected underdeployment.
B4. S3 26‐mm implantation result with a flared frame on the ventricular side. B5.
Left ventricular angiography to assess for MV regurgitation. B6. S3 26‐mm “round”
deployment. CT‐ID indicates computed‐tomography inner diameter; MV, mitral valve;
S3, Sapien 3; T‐ID, true inner diameter; VIV, valve‐in‐valve.
In order to facilitate suitable valve sizing, Bapat et al have developed a mobile
app “ViV Aortic” and “ViV Mitral” in collaboration with the technology company UBQO.15
This app provides data that guide proper identification of all available surgical
and transcatheter valves and rings, as well an in vitro estimate of the valve T‐ID,
and sizing recommendation for the S3 THV.3 Although the ViV App (version 2.0) is invaluable,
there are a few limitations of this App when using the Edwards S3 valve for VIV. The
ViV App sizing recommendation may in some cases exceed the optimal THV size for a
selected bioprosthesis. For example, the 21‐mm Perimount valve (Edwards Lifesciences)
has a 19‐mm T‐ID, and the App recommends selecting a 23‐mm Sapien XT or S3 THV (Edwards
Lifesciences).3 This may lead to inadequate expansion of the 23‐mm valve within the
bioprosthesis frame, leading to prosthesis–patient mismatch with possible higher transvalvular
gradients and inadequate function of the valve leaflets, and hence a 20‐mm Sapien
3 could be a better option with just 1‐mm oversizing. In this situation, our preferred
approach is to use high‐pressure postdilatation after 20‐mm S3 valve deployment to
optimize expansion and stretching of the bioprosthetic frame and sewing ring16 or
consider implanting a supra‐annular THV; however, if there is adequate space in the
aortic root, then “cracking the ring” with high‐pressure postdilatation technique
(described below) can enable implantation of a 23‐mm S3 THV (Figure 5).
Figure 5
Examples of using high‐pressure postdilatation to optimize THV deployment in small
bioprosthetic valves. Contrast and brightness are adjusted to minimize blooming artifact.
A. Edwards S3 20‐mm THV inside a Perimount 21 valve (true inner diameter 19 mm). A1.
Stent inner diameter of the Perimount sewing ring measured on the baseline CT—18.1×18.9 mm.
A2. Twenty‐mm S3 angiographic appearance after deployment. Note the waist appearance
at the level of the sewing ring. A3. Angiographic appearance of the 20‐mm S3 after
postdilatation with a 20‐mm True Dilatation balloon (Bard) to 16 atmospheres showing
improved device expansion within the bioprosthesis. A4. Stent inner diameter of the
Perimount sewing ring on CT after high‐pressure postdilatation showing increased dimensions
of 18.9×20.1 mm. A residual transvalvular mean gradient of 12 mm Hg was observed on
echocardiography. B. Edwards S3 23‐mm THV inside a Perimount 21 valve (true inner
diameter 19 mm). B1. Stent inner diameter of the Perimount sewing ring measured on
the baseline CT—18.4×20.2 mm. B2. Twenty‐three‐mm S3 angiographic appearance after
deployment. Note the mild waist appearance at the level of the sewing ring. B3. Angiographic
appearance of the 23‐mm S3 after postdilatation with a 22‐mm Atlas Gold balloon (Bard)
to 20 atmospheres showing improved device expansion within the bioprosthesis. B4.
Stent inner diameter of the Perimount sewing ring on CT after high‐pressure postdilatation
showing increased dimensions of 20.2×20.1 mm. A residual transvalvular mean gradient
of 18 mm Hg was observed on echocardiography. CT indicates computed tomography; S3,
Sapien 3; THV, transcatheter heart valve.
Balloon‐Sizing and Tug‐Test
Balloon sizing is not routinely recommended in VIV procedures, as there is an increased
risk of embolization or creating aortic insufficiency,1, 2, 4, 6 which can result
in acute hemodynamic instability. However, in addition to selecting the size of the
THV based on the T‐ID of the initially implanted bioprosthetic valve, balloon sizing
can provide additional information and better understanding in selected cases such
as when the CT‐ID suggests a smaller size S3 may be suitable, borderline valve sizes,
stentless bioprostheses, or valves with a high risk of coronary artery obstruction.
In these situations, balloon sizing can be performed along with a tug‐test (Figures 4
and 6). The tug‐test involves applying negative tension to the fully inflated balloon
within the bioprosthetic valve to help assess how well the balloon is anchored in
the valve. This information can be used to guide the selection of the appropriate
THV size and to assess the solidity of any material that may be accumulated within
the bioprosthesis.
Figure 6
Balloon‐sizing, tug‐test, and S3 overdeployment. Case of S3 23‐mm valve inside a Mitroflow
27‐mm valve with a T‐ID of 23 mm. The VIV Aortic App recommends implanting a S3 26‐mm
valve in this circumstance. Planned overdeployment of a S3 23‐mm (+2 mL in deployment‐balloon)
THV after balloon‐sizing and tug‐test with a 23‐mm balloon. A. Coplanar View. B. Balloon
sizing and the tug‐test show that the coronary arteries are not obstructed, and the
balloon is fixed in the bioprosthetic surgical valve. C. Placement of the S3 23‐mm
middle marker is at the bottom of the suture ring of the bioprosthetic surgical valve
(“low position”). D. Implantation result shows no aortic insufficiency with a peak‐to‐peak
gradient of 5 mm Hg across this valve. S3 indicates Sapien 3; THV, transcatheter heart
valve; T‐ID, true inner diameter; VIV, valve‐in‐valve.
Balloon sizing can be useful when the pre‐existing valve is supra‐annular with external
leaflets, such as the Mitroflow (Sorin) and Trifecta (Abbott), and there is a short
distance to the coronary ostia, thereby increasing the risk of coronary artery obstruction.2,
4, 5, 6 Furthermore, balloon sizing may be useful to assess for height of the prosthetic
valve neo‐annulus and to assess for unanticipated expansion of a stentless bioprosthesis,
a technical issue that can lead to THV embolization.17
Prosthesis–Patient Mismatch
Prosthesis–patient mismatch (PPM) is the phenomenon when the implanted prosthetic
valve has a lower effective orifice area (EOA) than a normal human valve.18 Calculations
based on patients’ body surface area, direct measurements of the aortic root during
surgery, and echocardiographic parameters such as transvalvular gradient and EOA are
calculated to assess PPM. In general, an echocardiographically derived prosthetic
EOA, indexed to body surface area (indexed EOA), of ≤0.60 cm2/m2 is considered severe,
of 0.60 to 0.85 cm2/m2 is moderate, and ≥0.85 cm2/m2 is considered nonsignificant.19,
20, 21 Based on the surgical literature, severe PPM following aortic valve replacement
is associated with worse clinical outcomes, less reduction in left ventricular mass,
and lower long‐term survival.22, 23 Likewise, severe PPM following surgical mitral
valve replacement is also associated with lower long‐term survival.24
Aortic VIV procedures are associated with a higher rate of PPM than native valve TAVR,6,
25 particularly in surgical valves with a manufacturer size of ≤21 mm.25 Results from
the VIVID registry revealed an elevated postprocedural mean aortic transvalvular gradient
of ≥20 mm Hg in 28% of patients.
When considering a VIV procedure, it is important to determine whether a high gradient
across a surgical valve is because of degeneration of the valve or simply as a result
of postoperative PPM.26 A VIV procedure will not correct a stable elevated transvalvular
gradient caused by surgical PPM unless an adjunctive technique—such as bioprosthetic
ring fracture—can be used.
Treatment of small bioprosthetic valves (label size ≤21 mm) remains a challenging
problem during aortic VIV procedures because of the risk of high postprocedural transvalvular
gradient with new, or persistent, PPM.6 As a result, a preprocedural evaluation of
the EOA may be particularly important to determine appropriate clinical management
and THV implantation strategy; however, in selected cases the benefit of acute gradient
reduction and hemodynamic improvement in highly symptomatic patients at prohibitive
risk of re‐do surgery may, nevertheless, outweigh the risk of PPM that can occur after
a VIV procedure. More recently, deliberate bioprosthetic sewing ring fracture (discussed
below) using high‐pressure balloon dilatation (“cracking‐the‐ring”) has emerged as
a promising adjunct for aortic VIV in a small bioprosthesis in order to facilitate
implantation of a larger THV size and effectively reduce postprocedural gradients.27,
28
Balloon‐Inflatable Versus Self‐Expanding THVs in VIV Procedures
Registry and in vitro data suggest that supra‐annular THVs are associated with lower
gradients after aortic VIV procedures; however, technical factors, such as future
access to the coronary vessels, concerns about THV recoil associated with self‐expanding
devices, or use of deliberate bioprosthetic ring fracture, may prompt selection of
a balloon‐expandable intra‐annular THV.11, 16, 29, 30, 31, 32 While randomized comparisons
of the transvalvular gradient after S3 versus supra‐annular THV implantation in surgical
bioprostheses have not been performed, accurate sizing, positioning, and deployment
of the S3 is clearly essential in order to achieve a good functional outcome with
low transvalvular gradients.
It should be noted that because of anatomical constraints, balloon‐expandable valves
are currently mandated in mitral VIV procedures.
Anticipating Complications During VIV Procedures
The risk of potential complications can often be determined by rigorous evaluation
of preprocedural investigations. The MDCT data, in particular, provide valuable information
when assessing the risk of severe intraprocedural complications.
During aortic VIV procedures, coronary artery occlusion may occur because of impingement
of displaced surgical leaflets and/or bulky degenerative material on the coronary
ostia, especially in stentless valves and valves with leaflet attachment outside the
frame, such as the Mitroflow (Sorin Group) and the Trifecta (Abbott) valves. In this
regard, MDCT enables accurate assessment of the height of the coronary ostia in relation
to the surgical bioprosthesis and the width of the aortic sinus. Low coronary height
(<12 mm) and/or small sinus of Valsalva diameter (<30 mm) will increase the risk for
coronary artery obstruction during native valve TAVR,33 and aortic VIV procedures
are associated with a higher risk.29 Unfavorable anatomy identified on MDCT may prompt
avoidance of a VIV procedure altogether; it may also direct the implanter to use balloon
sizing, or use a risk‐minimization strategy, such as less aggressive valve oversizing
and deeper valve implantation, to avoid coronary artery occlusion. A recently described
first‐in‐humans procedure involving intentional laceration of the bioprosthetic leaflet
scallop before valve implantation (BASILICA) may enable a successful aortic VIV procedure
despite a high risk of coronary occlusion (unpublished data—TCT 2017).
Mitral VIV poses a unique set of challenges to the operator. Closing pressure is higher
across bioprosthetic valves in the mitral position when compared with those in the
aortic position; this is because of exposure to left ventricular systolic, rather
than aortic diastolic, pressure. For this reason, secure anchoring of a VIV THV may
be more important in the mitral position than the aortic. The principles of MDCT‐based
valve sizing also apply to mitral VIV.
Mitral VIV also carries with it a risk of left ventricular outflow tract (LVOT) obstruction
because of displacement of the bioprosthetic leaflets and coverage of the open part
of the THV frame. Mitral VIV‐induced LVOT obstruction with hemodynamic compromise
is a serious complication with limited treatment options and can be fatal; therefore,
it should be avoided whenever possible. Bioprostheses with bovine pericardial leaflets
are at particular risk of creating a LVOT obstruction because the leaflets are positioned
higher up the stent frame, thus resulting in greater THV frame coverage in the LVOT.
Assessing the LVOT tract anatomical morphology with MDCT can be helpful to identify
patients at high risk of this complication.34 Prominent septal hypertrophy and a narrow
aorto‐mitral angle increase the risk of subsequent LVOT obstruction. The aorto‐mitral‐annular
angle—defined as the angle formed at the intersection of lines running through the
intercommissural diameter of the mitral annulus and the center of the aortic annulus—is
readily determined from preprocedural MDCT images. Acute angles <115 degrees may increase
the risk of LVOT obstruction after deployment of a balloon‐expandable valve35 (Figure 4).
Preprocedural virtual valve implantation, performed using commercially available 3‐dimensional
reconstruction software, and calculation of the neo‐LVOT area can assist preemptive
identification of this complication (Figure 7). Preliminary studies suggest that a
neo‐LVOT area of 250 mm2 or larger is associated with a low risk of LVOT obstruction.36,
37
Figure 7
Mitral annular area and neo‐LVOT area measurements. A, Cardiac computed tomography–based
measurement of the mitral internal annular area using 3Mensio Structural Heart Mitral
Workflow version 8.1 (Pie Medical Imaging, Maastricht, the Netherlands). B, Short‐axis
view of the mitral bioprosthesis with a 23‐mm virtual valve in place (pink circle).
C, Measurement of the LVOT tract area in systole in short‐axis (white circle) view
using 3Mensio Structural Heart Mitral Workflow version 8.1 (Pie Medical Imaging, Maastricht,
the Netherlands). D, Measurement of the remaining LVOT area in short axis (white circle)
after placement of the virtual transcatheter heart valve (pink). The remaining space
in the LVOT after placement of the virtual valve is the neo‐LVOT. A neo‐LVOT area
of 250 mm2 or larger is associated with a low risk of LVOT obstruction. LVOT indicates
left ventricular outflow tract.
Our S3 THV Sizing Recommendation for VIV Implantation
When using the S3 THV for VIV, we recommend a minimum oversizing of 1 mm in relation
to the T‐ID. However, when the measured CT‐ID suggests that a smaller size THV could
be selected, we would recommend balloon sizing and tug testing to confirm adequate
anchoring before implanting the smaller size. A simple algorithm for choosing the
S3 THV size is provided in Figure 2. In borderline cases between 2 S3 THV sizes (oversizing
range of 0–1 mm based on T‐ID or CT‐ID), the smaller S3 valve can be safely overexpanded
in order to optimize valve leaflet function and ensure anchoring10 (Figure 6). Furthermore,
overexpansion by overfilling of the deployment balloon with additional volume results
in further flaring, mainly of the in‐ and outflow segments of the S3 valve10; this
may also play a role in better fixation of the S3 THV within bioprosthetic surgical
valves. During mitral VIV procedures in particular, some degree of flaring of the
ventricular portion of the S3 is recommended to avoid late atrial dislodgement.34
Surgical Bioprosthetic Sizing Charts
Tables S1 and S2 show the published T‐ID, available in the Aortic VIV and Mitral VIV
apps, for selected stented bioprosthetic valves, in the aortic and mitral positions,
respectively. We recommend ≥1 mm oversizing when implanting a S3 THV within a stented
bioprosthesis. Based on this recommendation, a smaller S3 could be utilized in a number
of cases compared with the VIV app recommendation. For example, the 27‐mm Mitroflow
valve (Sorin) has a T‐ID of 23 mm and the ViV Aortic App recommends selecting a 26‐mm
S3 valve.3 However, an overdeployed 23‐mm S3 valve achieved an excellent final result
(Figure 6).
Stentless and Sutureless Surgical Bioprosthetic Valves
The surgical technique used for implantation of stentless and sutureless bioprosthetic
valves could vary the T‐ID of these valves. Walther et al described implantation of
oversized stentless surgical valves in patients with a small aortic root using controlled
oversizing and adjusting the valve size to the sinotubular junction diameter.38 They
were able to achieve a gain of 2 to 4 mm in prosthesis size with improved hemodynamics
based on this controlled oversizing.38 Thus, for stentless and sutureless surgical
valves (Table S3) we recommend MDCT‐based sizing. Measurement of the CT‐ID, which
matches with the internal diameter of the sewing ring (“neo‐annulus”), and assessment
of the amount of degenerative material, such as pannus or calcification in and around
the valve, is important and should be taken into consideration.
Valve in THV
Because of the recent popularity of TAVR, failed THVs are likely to account for an
increasing proportion of VIV procedures. Because of the common practice of oversizing
self‐expanding transcatheter valves, and the variability in final internal diameter,
CT measurements of the size of the native annulus should be taken into consideration.
In the majority of patients with a prior Sapien, Sapien XT, or S3 valve, the same
size S3 THV can be implanted. For example, if a patient has a failed 23‐mm Sapien
XT valve, then we would recommend implanting a 23‐mm S3 THV inside this failed THV.
Intraprocedural Considerations: Aortic VIV
To facilitate accurate THV landing zone evaluation, stented surgical valves should
be aligned fluoroscopically so that the basal ring and struts form a single plane
perpendicular to the imaging beam. This coplanar view can usually be achieved by aligning
the stent strut tips, the suture ring of stented valves, or the nadir points of stentless
valves39 (Figure 8).
Figure 8
Coplanar alignment of stented surgical bioprosthetic valves. Varying alignment of
the coplanar view: A. Overlap of struts, B. Struts in 1 line, C. Stent top markers
in 1 line. Stented surgical valves can be aligned based on the top markers/struts
of the valve, the suture ring, or angiographically at the nadir of the cusps of the
leaflets. The dotted red line represents the suture ring or the stent strut tips of
the surgical valve. The length of the middle marker is 3 mm on the S3 THV. The figure
depicts the accurate placement of the S3 THV along the dotted red line: 1, Predetermined
overexpansion (“low position”); 2, Predetermined nominal deployment (3–5 mm above
the suture ring); 3, Predetermined underexpansion (“high position”). S3 indicates
Sapien 3; THV, transcatheter heart valve.
To ensure an optimal valve deployment with safe anchoring and good sealing, the skirt
of the S3 valve should be implanted at the height of the “neo‐annulus” of the surgical
bioprosthetic valve. The neo‐annulus is almost always located at the level of the
surgical valve sewing ring; however, fluoroscopic identification of the location of
the sewing ring can vary depending on the valve type.14
In stented valves, the base of the S3 central radiopaque marker should be placed 3
to 5 mm above the suture ring when using nominal deployment volumes. In case of the
Mosaic valve (Medtronic), where the top markers of the outflow struts are the only
fluoroscopically visible markers, the aortic edge of the crimped S3 stent frame should
be placed 2 mm above the aortic edge of the markers in nominally deployed valves.
In stentless and sutureless aortic bioprosthesis, the “neo‐annulus” should be angiographically
aligned and the base of the S3 central marker should be placed at the height of the
“neo‐annulus.” If possible, the frame of the S3 should cover the neo‐annulus and the
leaflet of the bioprosthesis. A pigtail can be positioned in the aortic root to assist
accurate alignment with the annulus.
When treating failed supra‐annular and intra‐annular TAVR devices, the S3 should,
if possible, be deployed so that its frame covers the native aortic valve annulus
and the leaflets of the first device.
During deployment of the S3 THV, it should be kept in mind that the foreshortening
of the valve occurs predominantly from the inflow side of the valve during the late
stage of valve expansion. For this reason, the deployment height of the S3 during
VIV procedures should be adjusted to compensate for this foreshortening. Figure 8
shows an example of various coplanar views of surgical bioprosthetic valves, and where
to position the 3‐mm‐long central marker of the S3 valve in relation to the suture
ring of the aligned surgical valve based on the predetermined nominal deployment,
overexpansion, or underexpansion THV strategy.
Intraprocedural Considerations: Mitral VIV
The fluoroscopic alignment of the initially implanted mitral bioprosthesis is performed
in a similar manner to Ao VIV procedures. Based on analysis using the Sapien XT valve,
a THV deployment position that is too far into the ventricle may be associated with
an increased risk of LVOT obstruction.35 For a given valve size, the frame height
of the S3 THV is at least 3 mm greater than the Sapien XT.35 In contrast to the Sapien
XT, foreshortening of the S3 occurs from the atrial side and the extent is dependent
on whether the valve is under‐, over‐, or nominally deployed. For this reason, we
recommend that during nominal valve deployment the initial alignment of the S3 be
performed by positioning the ventricular edge of the frame with the ventricular edge
of the bioprosthesis. If an underexpansion strategy is chosen, then a more ventricular
initial alignment may be necessary to avoid an excessively atrial implantation; conversely,
more atrial alignment may be useful during planned valve overexpansion in order to
avoid an overly ventricular final position. If the anticipated risk of LVOT obstruction
is not excessive, flaring of the ventricular portion of the S3 frame with the deployment
balloon (nominal filling volume +1–2 mL) during valve implantation, or postdilatation,
may be considered to reduce the risk of atrial embolization.
Intraprocedural Considerations: Bioprosthetic Valve Fracture and High‐Pressure Balloon
Postdilatation
Small bioprosthetic valves (label size ≤21) treated with VIV TAVR are at high risk
of elevated postprocedural gradient and patient–prosthesis mismatch. Controlled cracking
of the polyester loop within the valve sewing ring using high‐pressure balloons has
been described in vitro and in a small number of in vivo cases for surgical valves
implanted in the pulmonary position40 with meaningful reductions in postprocedural
gradient. In vitro, the frames of the Mitroflow, Magna, Magna Ease, and Mosaic,27
plus the Biocor Epic and Perimount40 bioprosthetic surgical valves have been successfully
fractured using high‐pressure True Dilatation and Atlas Gold balloons (Bard Peripheral
Vascular). Balloon‐rated burst pressure was exceeded in all cases and fracture of
valves with metal sewing rings was not possible. Chhatriwalla et al subsequently reported
successful in vivo bioprosthetic valve fracture—in patients with bioprosthetic valves
≤label size 21 in the aortic position—with a reduction in mean transvalvular gradient
and an increase in valve EOA in 20 consecutive clinical cases; valve fracture was
performed either before or after the VIV TAVR.28 More recently, high‐pressure postdilatation
has been shown to improve transvalvular gradients in small bioprostheses even if sewing
ring fracture is not achieved.16
Bioprosthetic valve fracture may allow satisfactory deployment of a larger THV than
would otherwise be feasible, thus potentially correcting pre‐existing PPM when treating
small bioprosthetic valves (Figure 5). Care should be taken to ensure that there is
adequate space within the aortic root anatomy to allow safe implantation of a larger
THV.
High‐pressure balloon dilatation can be performed before or after valve implantation.
The former strategy may enable more reliable fracture of the bioprosthetic ring with
the potential disadvantages of inducing hemodynamically unstable severe aortic regurgitation,
and an increased risk of annulus rupture. The latter approach reduces the risk of
acute valvular insufficiency but may increase the difficulty in achieving ring fracture
and the risk of injuring the THV leaflets. In most cases our preference is to perform
high‐pressure balloon dilatation after implantation of the THV; however, this novel
technique may also be associated with an elevated risk of embolization of degenerated
valve material, rupture of the aortic root, coronary obstruction, and heart block.27,
28
Conclusion
VIV implantation is a feasible alternative to reoperation for a failed initial bioprosthetic
valve. The use of the S3 THV for VIV implantation in a failed aortic and mitral bioprosthesis
has recently received US Food and Drug Administration approval; the outer skirt of
the S3 valve and the ability to overexpand its frame make it a suitable device for
the VIV procedure. The selection of the S3 size should be based on the T‐ID of the
initially implanted bioprosthetic valve; however, CT imaging and determination of
the CT‐ID may influence the choice of S3 THV size in VIV procedures.
Disclosures
Dr Kasel is a medical consultant for and receives research support from Edwards Lifesciences.
Dr Kodali is a consultant for Edwards Lifesciences and Medtronic. Dr Leon is a medical
consultant for and receives research support from Edwards Lifesciences. Dr Schunkert
has received grants and personal fees from AstraZeneca, MSD Sharp & Dohme, AMGEN,
Bayer Vital, Medtronic, Novartis, and Sanofi, Pfizer, St. Jude Medical, Boston Scientific,
and Daiichi‐Sankyo; and personal fees from Brahms GmbH, Mitsubishi Pharma, Servier,
Takeda, Cordis, Genzyme, and Synlab. Dr Bapat is a consultant for Edwards Lifesciences,
Medtronic Inc, Boston Scientific, Abbott, and 4 Tech. Dr Guerrero has served as a
proctor and consultant and has received research grant support from Edwards Lifesciences.
Dr Dvir is a consultant for Edwards Lifesciences. The remaining authors have no disclosures
to report.
Supporting information
Table S1. Stented Bioprosthetic Surgical Aortic Valves
Table S2. Stented Bioprosthetic Mitral Valves
Table S3. Stentless, Sutureless, and Transcatheter Bioprosthetic Aortic Valves
Click here for additional data file.